X4 Pharmaceuticals, Inc (XFOR) — SEC Filings
X4 Pharmaceuticals, Inc (XFOR) — 47 SEC filings. Latest: 10-Q (May 6, 2026). Includes 24 8-K, 8 SC 13G/A, 7 10-Q.
View X4 Pharmaceuticals, Inc on SEC EDGAR
Overview
X4 Pharmaceuticals, Inc (XFOR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 5, 2025: X4 Pharmaceuticals, Inc. (XFOR) reported a significant increase in total revenue to $32.545 million for the nine months ended September 30, 2025, up from $1.123 million in the same period of 2024, primarily driven by $28.293 million in license and other revenue and $4.252 million in product revenue
Sentiment Summary
Across 47 filings, the sentiment breakdown is: 2 bearish, 43 neutral, 2 mixed. The dominant filing sentiment for X4 Pharmaceuticals, Inc is neutral.
Filing Type Overview
X4 Pharmaceuticals, Inc (XFOR) has filed 7 10-Q, 24 8-K, 2 DEF 14A, 2 10-K, 8 SC 13G/A, 4 SC 13G with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (47)
Risk Profile
Risk Assessment: Of XFOR's 33 recent filings, 2 were flagged as high-risk, 17 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $32,545,000 |
| Net Income | -$55,274,000 |
| EPS | N/A |
| Debt-to-Equity | 1.65 |
| Cash Position | $69,632,000 |
| Operating Margin | -194% |
| Total Assets | $163,555,000 |
| Total Debt | $76,062,000 |
Industry Context
The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like X4 Pharmaceuticals compete based on the innovation and efficacy of their drug candidates. The market for treatments for rare diseases and chronic conditions is growing, but competition from established players and emerging biotech firms is intense. Success hinges on navigating clinical trials, securing regulatory approvals, and effective commercialization strategies.
Top Tags
disclosure (5) · biotech (5) · Biotechnology (4) · 8-K (4) · material-agreement (4) · corporate-governance (4) · 10-Q (4) · financials (4) · institutional-ownership (4) · filing (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenue | $32.545M | Increased from $1.123M for the nine months ended September 30, 2024 |
| Net Loss | $55.274M | Increased from a net income of $2.371M for the nine months ended September 30, 2024 |
| Net Cash Used in Operating Activities | $70.091M | For the nine months ended September 30, 2025 |
| Net Proceeds from Private Placement | $81.0M | Closed on August 13, 2025 |
| Net Proceeds from Underwritten Offering | $145.6M | Closed on October 27, 2025 |
| Cash and Cash Equivalents | $69.632M | As of September 30, 2025, up from $55.699M at December 31, 2024 |
| Accumulated Deficit | $570.6M | As of September 30, 2025 |
| Reverse Stock Split | 1-for-30 | Effected on April 28, 2025 |
| Expected Full Enrollment | Q3 2026 | For the 4WARD Phase 3 clinical trial |
| Gain on Sale of Non-Financial Asset | $105.000M | Recorded in 2024, absent in 2025 |
| SEC File Number | 001-38295 | Identifies the company's filing with the SEC |
| IRS Employer Identification No. | 27-3181608 | Company's tax identification number |
| Report Date | 20250811 | The filing pertains to events on this date. |
| Filing Date | 20250812 | The report was officially filed on this date. |
| Product Revenue | $0 | No product revenue for the three and six months ended June 30, 2025, indicating no commercialized products. |
Frequently Asked Questions
What are the latest SEC filings for X4 Pharmaceuticals, Inc (XFOR)?
X4 Pharmaceuticals, Inc has 47 recent SEC filings from Jan 2024 to May 2026, including 24 8-K, 8 SC 13G/A, 7 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of XFOR filings?
Across 47 filings, the sentiment breakdown is: 2 bearish, 43 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find X4 Pharmaceuticals, Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all X4 Pharmaceuticals, Inc (XFOR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for X4 Pharmaceuticals, Inc?
Key financial highlights from X4 Pharmaceuticals, Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for XFOR?
The investment thesis for XFOR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at X4 Pharmaceuticals, Inc?
Executive information for X4 Pharmaceuticals, Inc is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for X4 Pharmaceuticals, Inc stock?
Of XFOR's 33 assessed filings, 2 were flagged high-risk, 17 medium-risk, and 14 low-risk.
What are recent predictions and forward guidance from X4 Pharmaceuticals, Inc?
Forward guidance and predictions for X4 Pharmaceuticals, Inc are extracted from SEC filings as they are enriched.